Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins

Jian,Wen; Li,Xin; Kang,Jian; Lei,Yingfeng; Bai,Yinlan; Xue,Ying

doi:10.3892/etm.2018.6425

Antitumor effect of recombinant Mycobacterium smegmatis expressing MAGEA3 and SSX2 fusion proteins

Authors:
- Wen Jian
- Xin Li
- Jian Kang
- Yingfeng Lei
- Yinlan Bai
- Ying Xue
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Medical Oncology Center, Dongguan Kanghua Hospital, Dongguan, Guangdong 523080, P.R. China, Department of Basic Microbiology, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: July 9, 2018 https://doi.org/10.3892/etm.2018.6425
Pages: 2160-2166

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mycobacterium smegmatis (M. smegmatis), which is a nonpathogenic and fast-growing mycobacterium, is a potential vaccine vector capable of expressing heterologous antigens. Spontaneous humoral and cellular immune responses have been demonstrated against cancer/testis antigens (CTA), including melanoma‑associated antigen A (MAGEA) and SSX. In the present study, recombinant plasmids expressing MAGEA3 and SSX2 were constructed. The recombinant plasmids were transferred into M. smegmatis to generate the novel antitumor DNA vaccine. As MAGEA3 and SSX2 were in different ligation sequences, the two DNA vaccines were recombinant M. smegmatis MAGEA3‑SSX2 (rM.S‑MS) and recombinant M. smegmatis SSX2‑MAGEA3 (rM.S‑SM), respectively. The expression levels of Fusion proteins were assessed by western blotting. BALB/c mice were immunized with rM.S and western blot analysis was used to determine whether antibodies against MAGEA3 or SSX2 were produced in immunized mice. EC9706 cells were inoculated into BALB/c nude mice and the mice were maintained until an obvious visible tumor appeared on the back. Subsequently, the blood from the rM.S immunized BALB/c mice was injected into the BALB/c nude mice via the tail vein. In order to evaluate the antitumor effect of the vaccines, tumor volume and weight were measured 5 to 21 days after injection. Mice were euthanized on day 21 of tumor growth, and the tumor was dissected and weighed. The two fusion proteins were expressed in the rM.S and the specific fusion protein antibodies were expressed in the blood of immunized BALB/c mice. The tumor volumes and weight in the recombinant M. smegmatis MAGEA3 (rM.S‑M) and recombinant M. smegmatis SSX2 (rM.S‑S) groups were significantly reduced compared with the control group. Furthermore, the decrease in tumor volumes and weight in the rM.S‑MS and rM.S‑SM groups was more severe than in the rM.S‑M or rM.S‑S groups. There was no significant difference in the antitumor effect of the rM.S‑MS and rM.S‑SM groups. The present findings suggest that this rM.S may be a potential candidate therapeutic vaccine for the treatment of cancer.

View Figures

View References

1	Lizée G, Cantu MA and Hwu P: Less yin, more yang: Confronting the barriers to cancer immunotherapy. Clin Cancer Res. 13:5250–5255. 2007. View Article : Google Scholar : PubMed/NCBI
2	Stewart TJ and Abrams SI: How tumours escape mass destruction. Oncogene. 27:5894–5903. 2008. View Article : Google Scholar : PubMed/NCBI
3	Stewart TJ and Smyth MJ: Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev. 30:125–140. 2011. View Article : Google Scholar : PubMed/NCBI
4	Pierre-Audigier C, Jouanguy E, Lamhamedi S, Altare F, Rauzier J, Vincent V, Canioni D, Emile JF, Fischer A, Blanche S, et al: Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency. Clin Infect Dis. 24:982–984. 1997. View Article : Google Scholar : PubMed/NCBI
5	Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, Henao-Tamayo M, Ordway D, Sellers RS, Jain P, Chen B, et al: A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med. 17:1261–1268. 2011. View Article : Google Scholar : PubMed/NCBI
6	van Faassen H, Dudani R, Krishnan L and Sad S: Prolonged antigen presentation, APC-, and CD8+ T cell turnover during mycobacterial infection: Comparison with Listeria monocytogenes. J Immunol. 172:3491–3500. 2004. View Article : Google Scholar : PubMed/NCBI
7	Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR, Lifton MA, Gorgone DA, Fennelly GJ, Haynes BF, Jacobs WR Jr and Letvin NL: Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol. 80:1645–1652. 2006. View Article : Google Scholar : PubMed/NCBI
8	Sang M, Lian Y, Zhou X and Shan B: MAGE-A family: Attractive targets for cancer immunotherapy. Vaccine. 29:8496–8500. 2011. View Article : Google Scholar : PubMed/NCBI
9	Meek DW and Marcar L: MAGE-A antigens as targets in tumour therapy. Cancer Lett. 324:126–132. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, et al: Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA. 105:20422–20427. 2008. View Article : Google Scholar : PubMed/NCBI
11	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
12	Gjerstorff MF, Andersen MH and Ditzel HJ: Oncogenic cancer/testis antigens: Prime candidates for immunotherapy. Oncotarget. 6:15772–15787. 2015. View Article : Google Scholar : PubMed/NCBI
13	Van den Eynde BJ and van der Bruggen P: T cell defined tumor antigens. Curr Opin Immunol. 9:684–693. 1997. View Article : Google Scholar : PubMed/NCBI
14	Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F and Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 179:921–930. 1994. View Article : Google Scholar : PubMed/NCBI
15	Greve KB, Pøhl M, Olsen KE, Nielsen O, Ditzel HJ and Gjerstorff MF: SSX2-4 expression in early-stage non-small cell lung cancer. Tissue Antigens. 83:344–349. 2014. View Article : Google Scholar : PubMed/NCBI
16	Bloom JE and McNeel DG: SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. 7:50997–51011. 2016. View Article : Google Scholar : PubMed/NCBI
17	Greve KB, Lindgreen JN, Terp MG, Pedersen CB, Schmidt S, Mollenhauer J, Kristensen SB, Andersen RS, Relster MM, Ditzel HJ and Gjerstorff MF: Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability. Mol Oncol. 9:437–449. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chen L, Zhou WB, Zhao Y, Liu XA, Ding Q, Zha XM and Wang S: Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERα signaling. Int J Oncol. 40:1986–1994. 2012.PubMed/NCBI
19	Huang CJ, Chen RH, Vannelli T, Lee F, Ritter E, Ritter G, Old LJ and Batt CA: Expression and purification of the cancer antigen SSX2: A potential cancer vaccine. Protein Expr Purif. 56:212–219. 2007. View Article : Google Scholar : PubMed/NCBI
20	Türeci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG and Pfreundschuh M: The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 56:4766–4772. 1996.PubMed/NCBI
21	Bardarov S, Kriakov J, Carriere C, Yu S, Vaamonde C, McAdam RA, Bloom BR, Hatfull GF and Jacobs WR Jr: Conditionally replicating mycobacteriophages: A system for transposon delivery to Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 94:10961–10966. 1997. View Article : Google Scholar : PubMed/NCBI
22	Xu H, Crawford D, Hutchinson KR, Youtz DJ, Lucchesi PA, Velten M, McCarthy DO and Wold LE: Myocardial dysfunction in an animal model of cancer cachexia. Life Sci. 88:406–410. 2011. View Article : Google Scholar : PubMed/NCBI
23	Young SL, Murphy M, Zhu XW, Harnden P, O'Donnell MA, James K, Patel PM, Selby PJ and Jackson AM: Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int J Cancer. 112:653–660. 2004. View Article : Google Scholar : PubMed/NCBI
24	Luo Y, Henning J and O'Donnell MA: Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer. Clin Dev Immunol. 2011:7289302011. View Article : Google Scholar : PubMed/NCBI
25	Zhang H, Peng P, Miao S, Zhao Y, Mao F, Wang L, Bai Y, Xu Z, Wei S and Shi C: Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice. Scand J Immunol. 72:349–357. 2010. View Article : Google Scholar : PubMed/NCBI
26	Xu W, Chen L, Guo S, Wu L and Zhang J: Intranasal administration of recombinant Mycobacterium smegmatis inducing IL-17A autoantibody attenuates airway inflammation in a murine model of allergic asthma. PLoS One. 11:e01515812016. View Article : Google Scholar : PubMed/NCBI
27	Bange FC, Collins FM and Jacobs WR Jr: Survival of mice infected with Mycobacterium smegmatis containing large DNA fragments from Mycobacterium tuberculosis. Tuber Lung Dis. 79:171–180. 1999. View Article : Google Scholar : PubMed/NCBI
28	Kirkin AF, Dzhandzhugazyan KN and Zeuthen J: Cancer/testis antigens: Structural and immunobiological properties. Cancer Invest. 20:222–236. 2002. View Article : Google Scholar : PubMed/NCBI
29	Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch Pv, Schuler G and Lüftl M: MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res. 296:314–319. 2005. View Article : Google Scholar : PubMed/NCBI
30	Moeller I, Spagnoli GC, Finke J, Veelken H and Houet L: Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes. Cancer Immunol Immunother. 61:2079–2090. 2012. View Article : Google Scholar : PubMed/NCBI
31	Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ and Odunsi K: Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res. 12:398–404. 2006. View Article : Google Scholar : PubMed/NCBI
32	Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA and Morgan RA: Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. PLoS One. 9:e933212014. View Article : Google Scholar : PubMed/NCBI
33	Caballero OL and Chen YT: Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci. 100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
34	Hemminger JA, Toland AE, Scharschmidt TJ, Mayerson JL, Guttridge DC and Iwenofu OH: Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma. Mod Pathol. 27:1238–1245. 2014. View Article : Google Scholar : PubMed/NCBI
35	Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, et al: Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J Clin Oncol. 31:2396–2403. 2013. View Article : Google Scholar : PubMed/NCBI
36	Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC and Speiser DE: Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol. 174:1709–1716. 2005. View Article : Google Scholar : PubMed/NCBI
37	Ayyoub M, Hesdorffer CS, Metthez G, Stevanovic S, Ritter G, Chen YT, Old LJ, Speiser D, Cerottini JC and Valmori D: Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells. J Immunol. 172:7206–7211. 2004. View Article : Google Scholar : PubMed/NCBI
38	Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, et al: Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol. 168:1717–1722. 2002. View Article : Google Scholar : PubMed/NCBI